Close button
Enquiry IconContact Us
Logo

Parkinson's disease is a nervous system disorder that impairs movement control. Parkinson's disease develops when nerve cells (neurons) in the substantia nigra (SN) portion of the brain become damaged or die. The condition often begins slowly and worsens over time. Trembling, muscular stiffness, difficulty in walking, keeping body balance, and coordination are the few symptoms associated with Parkinson's disease. As the condition progresses, difficulty in speaking & sleeping, thinking & memory issues, and behavioral changes may occur. According to Parkinson's Foundation, Parkinson's disease is found more frequently in men than women. A higher incidence was found among men with the risk of around 1.5 times greater in men than women.It is most typically found in those over the age of 60. Medications as well as other therapeutics such as exercise can help relieve some of the symptoms of Parkinson’s disease. Important therapeutic mode for patients with Parkinson’s disease is medications such as levodopa, safinamide, pramipexole, benztropine, and selegiline.  

The global Parkinson’s disease therapeutic market is estimated to be valued at US$ 4,697.3 million in 2021 and is expected to exhibit a CAGR of 6.3% during the forecast period (2021-2028).

Figure 1. Global Parkinson’s Disease Therapeutic Market in Terms of Value (US$ million), By Region, 2021

Parkinson's Disease Therapeutics  | Coherent Market Insights

Increasing approvals for drugs used in Parkinson’s disease is expected to drive the global Parkinson’s disease therapeutic market growth during forecast period

Rising drug approvals for treatment of Parkinson’s disease is projected to boost the market growth during the forecast period. For instance, in August 2019, Kyowa Kirin Co., Ltd. a Japanese pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). It is used as adjunctive therapeutic to levodopa/carbidopa in adult patients experiencing ‘OFF’ episodes with Parkinson’s disease (PD). An off episode in Parkinson's disease occurs when a patient's medicines are not working properly, resulting in an increase in PD symptoms such as tremor and walking difficulties. NOURIANZ (istradefylline) is an adenosine A2A receptor antagonist used in Parkinson’s disease in the U.S. The medicine provides a novel non-dopaminergic once-a-day oral therapeutic option for patients with Parkinson’s disease.

CMI table icon

Parkinson’s Disease Therapeutic Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,697.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.3% 2028 Value Projection: US$ 7,195.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others
  • By Route of Administration: Oral, Injectable, Nasal, Transdermal, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH

Growth Drivers:
  • Increasing drugs approvals for treatment of Parkinson’s disease
  • Robust pipeline of new drugs in development for Parkinson’s disease 
Restraints & Challenges:
  • Rising side effects associated with drugs used for Parkinson’s disease treatment 

Figure 2. Global Parkinson’s Disease Therapeutic Market Share in Terms of Value (US$ Mn), By Drug Class, 2021

Parkinson's Disease Therapeutics  | Coherent Market Insights

Robust pipeline of new drugs in development for Parkinson’s disease is projected to propel the market growth over the forecast period

Robust pipeline of new drugs in development for Parkinson’s disease is expected to propel the Parkinson’s disease therapeutic market growth over the forecast period. For instance, in October 2021, according to Vanderbilt University, drug candidate mGlu4 PAM AP-472 for Parkinson’s disease entered phase 1 clinical trials. The clinical trial was initiated by Appello Pharmaceuticals Inc., a clinical-stage therapeutics company focused on searching innovative early-stage drug candidates for patients with Parkinson’s disease. The mGlu4 PAM AP-472 is designed to operate in conjunction with an existing Parkinson's disease medication, levodopa.

Global Parkinson’s Disease Therapeutic Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic has a devastating influence on the lives of many families across the world, as well as healthcare institutions and the global economy. During the COVID-19 epidemic, patients had trouble in getting their regular Parkinson's disease therapeutics. For instance, in August 2020, according to International Parkinson and Movement Disorder Society, the impact of COVID-19 on the quality of healthcare reported by Parkinson's disease patients found that COVID-19 reduced the quality of healthcare as well as worsened the symptoms and interrupted the access to medication access for Parkinson’s disease patients. Access to PD medication were negatively impacted by closing the routine clinical space, faltering delivery systems, and the inability to access dispensaries or pay for medication.

Global Parkinson’s Disease Therapeutic Market: Restraint

Rising side effects associated with drugs used in Parkinson’s disease therapeutic is projected to hamper the market growth during the forecast period. The Parkinson’s disease drugs side effects will have a negative impact on patient’s lives and have to be kept under control along with the symptoms. Impulsive and compulsive behavior are possible side effects of some Parkinson’s disease medications and can have a significant impact on the affected person. In addition the available medications may have an effect of blocking the Parkinson’s medications or interact in a way making symptoms worse.

Key Players                                                               

Major players operating in the global Parkinson’s disease therapeutic market include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH.

Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson’s disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson’s disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson’s disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.

 Key features of the study:

  • This report provides an in-depth analysis of the global Parkinson’s disease therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Parkinson’s disease therapeutic market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Parkinson’s disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global Parkinson’s disease therapeutic market

Detailed Segmentation:

  • Global Parkinson’s Disease Therapeutic Market, By Drug Class
    • Levodopa
    • Dopamine agonists
    • MAO-B inhibitors
    • Anticholinergics
    • Others
  • Global Parkinson’s Disease Therapeutic Market, By Route of Administration
    • Oral
    • Injectable
    • Nasal
    • Transdermal
    • Others
  • Global Parkinson’s Disease Therapeutic Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Parkinson’s Disease Therapeutic Market, By Region:
    • North America
      • By Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By  Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Levodopa
          • Dopamine agonists
          • MAO-B inhibitors
          • Anticholinergics
          • Others
      • By Route of Administration
        • Oral
        • Injectable
        • Nasal
        • Transdermal
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG
    • GlaxoSmithKline Plc.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Zydus Cadila
    • Reddy’s Laboratories
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Boehringer Ingelheim International GmbH

 “*” marked represents similar segmentation in other categories in the respective section.

FAQ

Frequently Asked Questions

The global Parkinson’s disease therapeutic market is estimated to be valued at US$ 4,697.3 million in 2021 and is expected to exhibit a CAGR of 6.3% between 2021 and 2028.

Factors such as increasing approvals for drugs used in Parkinson’s disease is expected to drive the market growth during the forecast period.

Levodopa segment is expected to hold a major market share during the forecast period in the Parkinson’s disease therapeutic segment.

The major factor hampering growth of the market include rising side effects associated with drugs used in Parkinson’s disease treatment.

Major players operating in the market include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.